Payment overview · 2025
General Payments
$210.90
12 reported records · 6 companies
Healthcare provider profile · identity verified
Ryan M. Thomas, MD
Allopathic & Osteopathic Physicians|Family Medicine · ATCHISON, KS · NPI 1942269121
Verified facts
What the public records show
CMS Open Payments records show Ryan M. Thomas, MD received $210.90 in general payments during 2025 across 12 reported records.
Lilly USA, LLC accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.21 | 29.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.79 | 24.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.79 | 23.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.30 | 8.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.05 | 7.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.76 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.90 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.79 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.79 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.79 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.79 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.79 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.55 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.55 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 252 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 40 |
| Losartan Potassium | Losartan Potassium | 160 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 131 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 30 |
| Alprazolam | Alprazolam | 97 | 23 |
| Metformin Hcl Er | Metformin Hcl | 93 | 23 |
| Allopurinol | Allopurinol | 89 | 23 |
| Omeprazole | Omeprazole | 87 | 20 |
| Metformin Hcl | Metformin Hcl | 85 | 21 |
| Potassium Chloride | Potassium Chloride | 84 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 24 |
| Xarelto | Rivaroxaban | 83 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 82 | suppressed |
| Simvastatin | Simvastatin | 82 | 24 |
| Gabapentin | Gabapentin | 81 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 13 |
| Jardiance | Empagliflozin | 68 | 12 |
| Furosemide | Furosemide | 67 | 15 |
| Eliquis | Apixaban | 64 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 11 |
| Famotidine | Famotidine | 59 | 12 |
| Tramadol Hcl | Tramadol Hcl | 56 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 16 |
| Sertraline Hcl | Sertraline Hcl | 51 | 11 |
| Carvedilol | Carvedilol | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.90 · 12 records | Lilly USA, LLC | ABRYSVO, COMIRNATY, JARDIANCE, MOUNJARO, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, UBRELVY, Veozah, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error